Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Sees Significant Drop in Short Interest

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) was the recipient of a significant decline in short interest in the month of February. As of February 13th, there was short interest totaling 24 shares, a decline of 96.7% from the January 29th total of 725 shares. Based on an average daily volume of 2,057 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the shares of the company are sold short. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 2,057 shares, the days-to-cover ratio is currently 0.0 days.

Hedge Funds Weigh In On Ascentage Pharma Group International

Large investors have recently added to or reduced their stakes in the company. Citadel Advisors LLC acquired a new position in shares of Ascentage Pharma Group International during the 3rd quarter worth approximately $383,000. XY Capital Ltd raised its position in Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after acquiring an additional 12,530 shares in the last quarter. UBS Group AG lifted its stake in Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after acquiring an additional 10,988 shares during the last quarter. ABC Arbitrage SA acquired a new stake in Ascentage Pharma Group International in the third quarter valued at $204,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Ascentage Pharma Group International in the 3rd quarter valued at about $96,000.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Rodman & Renshaw initiated coverage on shares of Ascentage Pharma Group International in a research report on Tuesday, January 13th. They issued a “buy” rating and a $48.00 price target for the company. Oppenheimer began coverage on shares of Ascentage Pharma Group International in a research report on Thursday, December 4th. They issued an “outperform” rating and a $45.00 target price for the company. Lucid Cap Mkts upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th. Piper Sandler assumed coverage on Ascentage Pharma Group International in a research note on Wednesday, November 5th. They set an “overweight” rating and a $48.00 target price for the company. Finally, BTIG Research started coverage on shares of Ascentage Pharma Group International in a research note on Monday, November 10th. They set a “buy” rating and a $50.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. According to MarketBeat, Ascentage Pharma Group International has a consensus rating of “Buy” and an average price target of $48.40.

Ascentage Pharma Group International Stock Up 0.2%

Shares of Ascentage Pharma Group International stock traded up $0.05 during trading on Wednesday, reaching $25.05. 536 shares of the company were exchanged, compared to its average volume of 3,132. The company has a quick ratio of 1.53, a current ratio of 1.54 and a debt-to-equity ratio of 1.31. The business has a 50-day moving average price of $26.01 and a 200-day moving average price of $32.90. Ascentage Pharma Group International has a twelve month low of $17.56 and a twelve month high of $48.45.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.